| Literature DB >> 26373279 |
Jinkuk Kim1, In-Hee Lee2, Hee Jin Cho3, Chul-Kee Park4, Yang-Soon Jung5, Yanghee Kim6, So Hee Nam6, Byung Sup Kim5, Mark D Johnson7, Doo-Sik Kong5, Ho Jun Seol5, Jung-Il Lee5, Kyeung Min Joo8, Yeup Yoon3, Woong-Yang Park9, Jeongwu Lee10, Peter J Park11, Do-Hyun Nam12.
Abstract
Tumor recurrence following treatment is the major cause of mortality for glioblastoma multiforme (GBM) patients. Thus, insights on the evolutionary process at recurrence are critical for improved patient care. Here, we describe our genomic analyses of the initial and recurrent tumor specimens from each of 38 GBM patients. A substantial divergence in the landscape of driver alterations was associated with distant appearance of a recurrent tumor from the initial tumor, suggesting that the genomic profile of the initial tumor can mislead targeted therapies for the distally recurred tumor. In addition, in contrast to IDH1-mutated gliomas, IDH1-wild-type primary GBMs rarely developed hypermutation following temozolomide (TMZ) treatment, indicating low risk for TMZ-induced hypermutation for these tumors under the standard regimen.Entities:
Mesh：
Substances：
Year: 2015 PMID： 26373279 DOI： 10.1016/j.ccell.2015.07.013
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743